ALZN 8-K: SEC filing

Alzamend Neuro

Filed with the SEC on · accession 0001214659-26-014554

ALZN filed a 8-K (current report) with the SEC on Nov 18, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Alzamend Neuro announced it will present at the annual meeting of the Society for Neuroscience on November 18, 2026, furnishing the presentation as Exhibit 99.1 under Regulation FD.

Key details

RegistrantAlzamend Neuro, Inc.
Conference host where company presentedSociety for Neuroscience
Chief financial officerDavid J. Katzoff

✦ Ask GOAX AI about this filing — what it means for ALZN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ALZN?

Click here

Frequently asked questions

What did ALZN file with the SEC on Nov 18, 2026?

ALZN filed a 8-K (SEC filing). Alzamend Neuro announced it will present at the annual meeting of the Society for Neuroscience on November 18, 2026, furnishing the presentation as Exhibit 99.1 under Regulation FD.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other ALZN SEC filings

Get alerts when ALZN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days